BACKGROUND Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely
A trial fibrillation (AF) is the most common arrhythmia in patients with heart failure with reduced ejection fraction (HFrEF), with a prevalence that increases with severity of heart failure (HF), reaching up to 50% in patients in New York Heart Association (NYHA) functional class IV (1, 2) . In some studies, AF has been associated with a poorer prognosis in HFrEF but this has not been a consistent finding after adjustment for other variables associated with worse outcomes. As a result, there is controversy about whether AF is an independent prognostic factor in HFrEF (3) (4) (5) .
The different findings reported may reflect the completeness of clinical data available for adjustment, including information related to medical history, comorbidity, and physiological and laboratory measurements. Notably, no study in chronic HFrEF included measurement of natriuretic peptides, the most powerful independent predictor of outcome in this condition. AF was also inconsistently defined in existing studies with some using medical history and others using the baseline electrocardiogram (ECG) to identify AF (4, 6) . Consequently, existing analyses have not examined whether type of AF (paroxysmal vs. persistent or permanent) is related to outcome. Similarly, the relationship between incident AF and outcomes has rarely been examined in previous studies.
To address these outstanding questions, we have Manuscript received September 6, 2017; accepted September 10, 2017.
Mogensen et al. of each group, respectively). Table 2 ).
DISCUSSION
We investigated the association between AF and outcomes in HFrEF. We found that, after adjustment for other prognostic variables, including natriuretic peptides, paroxysmal, but not persistent or permanent AF, was associated with a higher risk of the composite outcome of HF hospitalization or death from cardiovascular causes (Central Illustration). The higher risk was primarily related to an elevated risk of hospital admission for worsening HF. Paroxysmal AF was also Last, new onset (incident) AF conferred the greatest risk of all, being associated with a higher risk both of hospitalization and death, as well as of stroke.
Prior studies have reported conflicting findings as to whether AF is an independent predictor of adverse outcomes (3) (4) (5) (12) (13) (14) (15) (16) (17) (18) (19) . This conflict has been thought to reflect the varying level of adjustment for other prognostic variables as patients with AF have generally been older, had more severe HF, and more comorbidity than did those without AF. This has led to debate about whether AF is just a marker of more advanced disease in sicker patients, rather than an independent prognostic risk factor. When we examined all patients with a history of AF we found a similar picture to that described previously, although LVEF was slightly higher in patients with AF compared to those without. However, when we A unique aspect of the present study was the measurement of NT-proBNP at baseline. This is important because natriuretic peptides are the single Although the rate of use of beta-blocker was similar, the rate of use of digoxin in patients with paroxysmal Of note, new onset AF carried the greatest risk of all, including a heightened risk of death. Although the number of patients and events in this category was relatively small, we believe that it is real and has been reported previously (4, 6, 26) . Again the reasons for this are uncertain, although the same considerations discussed in relation to paroxysmal AF may apply. Hazard ratios (HRs) of outcomes according to type of atrial fibrillation (AF) using no AF as reference. HRs with 95% confidence intervals were calculated using cause-specific Cox models, adjusted for age, sex, region, race, New York Heart Association functional class, ejection fraction, heart rate, systolic blood pressure, estimated glomerular filtration rate, diabetes, body mass index, time since HF diagnosis, history of HF hospitalization, history of myocardial infarction, history of stroke, log N-terminal pro-B-type natriuretic peptide, and randomized treatment (enalapril, sacubitril/valsartan, aliskiren, or combination). The p values are for difference between paroxysmal and persistent or permanent AF. CV ¼ cardiovascular.
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